Evidence map›Paper›PMID 42425504›Full record

ReviewEuropean heart journal2026

The dark genome in cardiovascular medicine.

Despoina Kesidou, Simon D Brown, Lars Maegdefessel, Igor Ulitsky, Andrew H Baker

Abstract readReview
In one paragraph

Review in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Despoina KesidouInstitute for Neuroscience and Cardiovascular Research, Queens Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.ORCID 0000-0001-8671-7237
Simon D BrownInstitute for Neuroscience and Cardiovascular Research, Queens Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.ORCID 0000-0003-1679-4856
Lars MaegdefesselInstitute of Molecular Vascular Medicine, TUM University Hospital, Munich 80802, Germany.ORCID 0000-0001-5228-2634
Igor UlitskyDepartment of Immunology and Regenerative Biology and Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot 7610001, Israel.ORCID 0000-0003-0555-6561
Andrew H BakerInstitute for Neuroscience and Cardiovascular Research, Queens Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.ORCID 0000-0003-1441-5576

Funding

Abisch-Frenkel RNA Therapeutics CenterBritish Heart Foundation Chair of Translational Sciences CH/11/2/28733British Heart Foundation Chair of Translational Sciences EP/Z533373/1British Heart Foundation Chair of Translational Sciences RG/F/25/110149British Heart Foundation Research Excellence MR/Z504865/1Cluster for Nucleic Acid Sciences and Technologies-NUCLEATECNATM 03ZU1201BMDeutsche Forschungsgemeinschaft 533767322-EXC 3113/1DFG TRR267European Research Council 101088370Israeli Ministry of Health 3-19415UKRI Medical Research CouncilWeizmann Institute
6 · The paper itself

Abstract

Only ∼1%-2% of the human genome directly codes for proteins. The remainder consists of non-coding DNA, often referred to as the 'dark genome'. This includes regulatory elements, transposable and repetitive sequences, structural genomic features, pseudogenes, intronic and intergenic regions, and non-coding RNA (ncRNA) genes. These components are increasingly recognized as major regulators of gene expression, cell identity, and disease susceptibility. Currently, dark genome elements, particularly ncRNAs are increasingly recognized as important regulators of cardiovascular health and disease. Advances in genome analysis technologies have greatly improved our understanding of these non-coding regions and revealed clearer connections between the dark genome and cardiovascular traits. This review highlights major parts of the dark genome involved in cardiovascular disease, with emphasis on those for which mechanistic understanding and translational relevance are beginning to emerge. As mechanistic insight into individual and collective components of the dark genome advances, it increasingly enables the development of new opportunities for targeted therapeutics for cardiovascular prevention and disease management.

Indexed as

Cardiovascular DiseasesGenome, HumanDNA, IntergenicDNA Transposable ElementsHumansIntronsPseudogenesRepetitive Sequences, Nucleic AcidRNA, UntranslatedDNA, IntergenicDNA Transposable ElementsRNA, UntranslatedCardiovascular diseaseDark genomeNon-coding RNAs (ncRNAs)RNA therapeuticsTranscriptomicsTranslational cardiovascular medicine

Identifiers

PMID42425504
PMCPMC13533564

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.